This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EU Pharmaceutical Law Forum
Delivered as a Hybrid Event 17-19 May 2022
Live In-Person Event: 17-19 May, Steigenberger Wiltcher's, BrusselsDigital Experience: All presentation recordings on-demand for 10 days from 24th May

Jacqueline Mulryne
Partner at Arnold & Porter

Profile

Jackie Mulryne is a member of the Life Sciences practice group, and provides regulatory, policy and compliance advice to clients in the pharmaceutical, medical devices, cosmetics and foods sectors. She advises on complex UK and EU regulatory issues that arise throughout the product life cycle, including maximising regulatory protections and the overlap with IP rights, borderline classification, clinical research, authorisation, advertising and promotion, and market access strategy. She also helps companies develop and implement cross-border regulatory compliance programmes, audits and investigations.

In addition, Ms. Mulryne advises on privacy and data protection matters for life science and medical device companies, including the UK and EU framework under the General Data Protection Regulation (GDPR).

Ms. Mulryne specialises in contentious disputes in the sector, and has extensive experience in public and administrative law litigation before the national and EU Courts, in defending enforcement actions by the competent authorities at EU and national level, and in coordinating such matters across the EU. She advises on actions arising from the decisions of regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission and the European Medicines Agency (EMA), and represents clients challenging public procurement tenders under EU and UK rules.

Ms. Mulryne also works on product liability matters on behalf of pharmaceutical and medical device companies, and has assisted on large multiparty actions, and in defending individual personal injury and product liability claims.

Ms. Mulryne is committed to pro bono work, and has acted for a number of organisations and individuals before the UK and international courts.

Agenda Sessions

  • DUAL DIALOGUE New Developments in the Regulation, Conduct and Use of Real-World Evidence

    14:50